{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T18:29:51Z","timestamp":1788200991971,"version":"build-2803163510"},"reference-count":135,"publisher":"Informa UK Limited","issue":"12","funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30 CA016672"],"award-info":[{"award-number":["P30 CA016672"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30 CA013148"],"award-info":[{"award-number":["P30 CA013148"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Investigational Drugs"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1080\/13543784.2024.2434696","type":"journal-article","created":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T05:17:45Z","timestamp":1732771065000},"page":"1231-1244","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":3,"title":["Investigational drugs in early phase trials for myelofibrosis"],"prefix":"10.1080","volume":"33","author":[{"given":"Sankalp","family":"Arora","sequence":"first","affiliation":[{"name":"Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pankit","family":"Vachhani","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology and Oncology, The University of Alabama at Birmingham, Birmingham, AL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prithviraj","family":"Bose","sequence":"additional","affiliation":[{"name":"Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2024,11,27]]},"reference":[{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26050"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23690"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000595"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-017-3099-2"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.72"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-3145"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1110557"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1110556"},{"key":"e_1_3_4_11_1","unstructured":"U FDA. Drug approvals and databases 2024. Available from: https:\/\/www.fda.gov\/drugs\/development-approval-process-drugs\/drug-approvals-and-databases"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-13892-x"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.637512"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.34205"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02246"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature10509"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2014.05.016"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2005.06.027"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1091\/mbc.e09-05-0380"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.01365-08"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2011.08.017"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-3904"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2017.11.009"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-4071"},{"key":"e_1_3_4_25_1","volume-title":"EHA 2024 Annual Congress","author":"Vachhani P","year":"2024","unstructured":"Vachhani P, Hunter A, McMahon B, et al. Bromodomain and extra-terminal (BET) inhibitor INCB057643 in patients with relapsed or refractory myelofibrosis (MF) and other advanced myeloid neoplasms: a phase 1 study. In: EHA 2024 Annual Congress; Madrid, Spain; 2024 Jun 13."},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-09-245837"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.00633"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2012.03.027"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-04-569525"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000054"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-148682"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-181971"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2210"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2015.89"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-021-00791-1"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051113"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.1158\/2643-3230.BCD-22-0189"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-11-0324"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature11303"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2015.06.006"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaw3242"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-179369"},{"key":"e_1_3_4_43_1","unstructured":"Clinicaltrials.gov. A phase 1 open-label multicenter study of INCB160058 in participants with myeloproliferative neoplasms 2024. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06313593"},{"key":"e_1_3_4_44_1","doi-asserted-by":"publisher","DOI":"10.3892\/br.2015.561"},{"key":"e_1_3_4_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.febslet.2004.06.050"},{"key":"e_1_3_4_46_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2009.017079"},{"key":"e_1_3_4_47_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01464-2"},{"key":"e_1_3_4_48_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-180164"},{"key":"e_1_3_4_49_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1311347"},{"key":"e_1_3_4_50_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000622"},{"key":"e_1_3_4_51_1","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000333"},{"key":"e_1_3_4_52_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-159435"},{"key":"e_1_3_4_53_1","unstructured":"Clinicaltrials.gov. A study to evaluate INCA033989 administered in participants with myeloproliferative neoplasms 2024. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06034002"},{"key":"e_1_3_4_54_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-173430"},{"key":"e_1_3_4_55_1","unstructured":"Clinicaltrials.gov. A study of JNJ-88549968 for the treatment of calreticulin (calr)-mutated myeloproliferative neoplasms 2024. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06150157"},{"key":"e_1_3_4_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2020.11.003"},{"key":"e_1_3_4_57_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.9490"},{"key":"e_1_3_4_58_1","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/415024"},{"key":"e_1_3_4_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2022.10.009"},{"key":"e_1_3_4_60_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1079490"},{"key":"e_1_3_4_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2007.08.014"},{"key":"e_1_3_4_62_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.188.2.287"},{"key":"e_1_3_4_63_1","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2300362"},{"key":"e_1_3_4_64_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-188820"},{"key":"e_1_3_4_65_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.6580"},{"issue":"1","key":"e_1_3_4_66_1","first-page":"23","article-title":"Lysyl oxidase inhibition in primary myelofibrosis: a renewed strategy","volume":"1","author":"Piasecki A","year":"2020","unstructured":"Piasecki A, Leiva O, Ravid K. Lysyl oxidase inhibition in primary myelofibrosis: a renewed strategy. Arch STEM Cell Ther. 2020 Dec;1(1):23\u201327.","journal-title":"Arch STEM Cell Ther"},{"key":"e_1_3_4_67_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M111.243113"},{"key":"e_1_3_4_68_1","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2017.6"},{"key":"e_1_3_4_69_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23409"},{"key":"e_1_3_4_70_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-019-02751-6"},{"key":"e_1_3_4_71_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000970996.87048.d4"},{"key":"e_1_3_4_72_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14501"},{"key":"e_1_3_4_73_1","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.572"},{"key":"e_1_3_4_74_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-181383"},{"key":"e_1_3_4_75_1","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-10-183"},{"key":"e_1_3_4_76_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI154092"},{"key":"e_1_3_4_77_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.153.6.2819"},{"key":"e_1_3_4_78_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2015.141283"},{"key":"e_1_3_4_79_1","doi-asserted-by":"publisher","DOI":"10.1007\/s002770050595"},{"key":"e_1_3_4_80_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190500126463"},{"key":"e_1_3_4_81_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.95"},{"key":"e_1_3_4_82_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-04-1133"},{"key":"e_1_3_4_83_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-06-439661"},{"key":"e_1_3_4_84_1","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.145651"},{"key":"e_1_3_4_85_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-0276"},{"key":"e_1_3_4_86_1","doi-asserted-by":"publisher","DOI":"10.1038\/nri2990"},{"key":"e_1_3_4_87_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2009-1614"},{"key":"e_1_3_4_88_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2009.26"},{"key":"e_1_3_4_89_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20160283"},{"key":"e_1_3_4_90_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.112"},{"key":"e_1_3_4_91_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000051"},{"key":"e_1_3_4_92_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000971000.57384.96"},{"key":"e_1_3_4_93_1","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000516"},{"key":"e_1_3_4_94_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-05-432989"},{"key":"e_1_3_4_95_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021010986"},{"key":"e_1_3_4_96_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-118584"},{"key":"e_1_3_4_97_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(19)30236-4"},{"key":"e_1_3_4_98_1","unstructured":"FDA US. FDA approves treatment for rare blood disease 2021. Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-treatment-rare-blood-disease"},{"key":"e_1_3_4_99_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-180922"},{"key":"e_1_3_4_100_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-156389"},{"key":"e_1_3_4_101_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-07-170449"},{"key":"e_1_3_4_102_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2011.11.001"},{"key":"e_1_3_4_103_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2022.103862"},{"key":"e_1_3_4_104_1","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000001"},{"key":"e_1_3_4_105_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2012.03.018"},{"key":"e_1_3_4_106_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18044"},{"key":"e_1_3_4_107_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16010154"},{"key":"e_1_3_4_108_1","volume-title":"EHA 2024 Annual Congress","author":"Bose P","unstructured":"Bose P, Kiladjian JJ, Takeuchi M, et al. The activin receptor like kinase-2 inhibitor zilurgisertib (INCB000928) as monotherapy or with ruxolitinib in patients with anemia due to myelofibrosis: phase 1\/2 study results. In: EHA 2024 Annual Congress; Madrid, Spain. p. 6\/13\/20242024."},{"key":"e_1_3_4_109_1","doi-asserted-by":"publisher","DOI":"10.1159\/000208988"},{"key":"e_1_3_4_110_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-09-111567"},{"key":"e_1_3_4_111_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng1274"},{"key":"e_1_3_4_112_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI25049"},{"key":"e_1_3_4_113_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.2432"},{"key":"e_1_3_4_114_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2152-2650(24)00707-9"},{"key":"e_1_3_4_115_1","doi-asserted-by":"publisher","DOI":"10.3978\/j.issn.2306-9759.2016.02.03"},{"key":"e_1_3_4_116_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-020-04306-w"},{"key":"e_1_3_4_117_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000970872.10730.ab"},{"key":"e_1_3_4_118_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-152729"},{"key":"e_1_3_4_119_1","volume-title":"EHA 2024 Annual Congress","author":"Harrison C","year":"2024","unstructured":"Harrison C, Ross D, Palandri F, et al. Elritercept (KER-050) demonstrated potential to treat myelofibrosis and mitigate ruxolitinib-associated cytopenias in the phase 2 RESTORE trial. In: EHA 2024 Annual Congress; Madrid, Spain; 2024."},{"key":"e_1_3_4_120_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-03-488098"},{"key":"e_1_3_4_121_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-11-731604"},{"key":"e_1_3_4_122_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010298.pub2"},{"key":"e_1_3_4_123_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024012939"},{"key":"e_1_3_4_124_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2152-2650(23)01234-X"},{"key":"e_1_3_4_125_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.6502"},{"key":"e_1_3_4_126_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-173509"},{"key":"e_1_3_4_127_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-180844"},{"key":"e_1_3_4_128_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000967752.72578.ff"},{"key":"e_1_3_4_129_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.02864"},{"key":"e_1_3_4_130_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000975644.99899.f4"},{"key":"e_1_3_4_131_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(24)00067-X"},{"key":"e_1_3_4_132_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-22-0952"},{"key":"e_1_3_4_133_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-162621"},{"key":"e_1_3_4_134_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2010.07.015"},{"key":"e_1_3_4_135_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(17)30237-5"},{"key":"e_1_3_4_136_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024025802"},{"key":"e_1_3_4_137_1","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2023.2203318"}],"container-title":["Expert Opinion on Investigational Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13543784.2024.2434696","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T11:32:24Z","timestamp":1734694344000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13543784.2024.2434696"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,27]]},"references-count":135,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["10.1080\/13543784.2024.2434696"],"URL":"https:\/\/doi.org\/10.1080\/13543784.2024.2434696","relation":{},"ISSN":["1354-3784","1744-7658"],"issn-type":[{"value":"1354-3784","type":"print"},{"value":"1744-7658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,27]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieid20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieid20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2024-10-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-11-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-11-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}